eFFECTOR Therapeutics is a clinical-stage biopharmaceutical company focused on pioneering the discovery and development of a new class of oncology drugs known as selective translation regulators (STRs). Translation is the process in cells whereby the synthesis of proteins is directed by information contained in genetic sequences. Each of eFFECTOR’s product candidates is designed to act on a single protein that regulates, in a coordinated manner, the expression of multiple functionally related proteins that together drive important biological processes such as immune evasion, stress and inflammatory responses, as well as cell proliferation.
Location: United States, California, San Diego
Employees: 11-50
Phone: +1 858-546-3997
Total raised: $123.6M
Founded date: 2012
Investors 6
Date | Name | Website |
- | US Venture... | usvp.com |
- | Mission Bi... | missionbio... |
- | The Column... | thecolumng... |
- | Abingworth... | abingworth... |
- | Altitude L... | altitudels... |
- | SR One | srone.com |
Funding Rounds 3
Date | Series | Amount | Investors |
24.07.2017 | Series C | $38.6M | - |
22.12.2015 | Series B | $40M | - |
20.05.2013 | Series A | $45M | - |
Mentions in press and media 18
Date | Title | Description | Source |
08.06.2023 | eFFECTOR Therapeutics Raises a Total of $16.2 Million in Gro... | eFFECTOR Closes Second Registered Direct Offering Priced At-The-Market Under Nasdaq Rules /EIN News... | einpresswi... |
08.06.2023 | eFFECTOR Therapeutics Raises a Total of $16.2 Million in Gro... | - | globenewsw... |
10.01.2018 | Biopharma watchers arrive at rare consensus: 2018 will be bi... | Not one person said they expect total M&A activity to decline in the coming year, relative to 20... | medcitynew... |
24.07.2017 | eFFECTOR Therapeutics Raises $38.6M | San Diego-based eFFECTOR Therapeutics, a developer of treatments for cancer, has raised $38.6M in a ... | socaltech.... |
24.07.2017 | eFFECTOR Therapeutics Closes $38.6M Series C Financing | eFFECTOR Therapeutics, Inc., a San Diego, CA-based developer of selective translation regulators for... | finsmes.co... |
24.07.2017 | eFFECTOR Therapeutics Inks $38.6M Series C | SAN DIEGO, CA, Leader in the development of selective translation regulators for the treatment of ... | vcnewsdail... |
19.02.2016 | effector Therapeutics Increases Series B Financing to $56M | eFFECTOR Therapeutics, Inc., a San Diego, CA-based biopharmaceutical company developing selective tr... | finsmes.co... |
19.02.2016 | Effector Therapeutics bumps up Series B to $56M | The company says that eFT508 can regulate a number of cancer-driving and immune-signaling pathways –... | medcitynew... |
19.02.2016 | eFFECTOR Therapeutics Boosts Series B To $56M | San Diego-based eFFECTOR Therapeutics, which is developing gene translation technology to help in th... | socaltech.... |
22.12.2015 | eFFECTOR Therapeutics Picks Up $40M For Cancer Treatment... | San Diego-based eFFECTOR Therapeutics, a biopharmaceuticals startup focused on treatment of cancer, ... | socaltech.... |
Show more